Can a diabetes pill protect hearts of dialysis patients?

NCT ID NCT05179668

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested the drug dapagliflozin (a diabetes medicine) against a placebo in 220 people on dialysis for kidney failure, with or without diabetes. The goal was to see if the drug could improve heart structure and be safe. Participants took the drug or placebo for a period, and doctors measured heart changes using ultrasound and blood tests.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for KIDNEY FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome Hypertrophy, Left Ventricular kidney failure type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Dialyseinstitut Dr. Waller

    Feldbach, 8330, Austria

  • Dialyseinstitut Gießauf GmbH

    Graz, Austria

  • Hanusch Krankenhaus

    Vienna, 1140, Austria

  • Klinik Donaustadt

    Vienna, 1220, Austria

  • Klinik Favoriten

    Vienna, 1100, Austria

  • Klinik Landstraße

    Vienna, 1030, Austria

  • Krankenhaus Hietzing

    Vienna, 1130, Austria

  • Medical University of Vienna

    Vienna, 1090, Austria

  • Wiener Dialysezentrum

    Vienna, 1220, Austria